By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Ophthalmic steroids > Prednisol (ophthalmic) > Prednisolone Ophthalmic Dosage
Ophthalmic steroids
https://themeditary.com/dosage-information/prednisolone-ophthalmic-dosage-3785.html

Prednisolone Ophthalmic Dosage

Drug Detail:Prednisol (ophthalmic) (Prednisolone (ophthalmic) [ pred-nis-oh-lone-off-thal-mik ])

Drug Class: Ophthalmic steroids

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Iritis

0.12% and 1% Ophthalmic Suspensions: Instill 1 to 2 drops into the conjunctival sac of the affected eye(s) 2 to 4 times a day; during the initial 24 to 48 hours, may increase dosing frequency if necessary

Comments:

  • If signs/symptoms fail to improve after 2 days of treatment, the patient should be re-evaluated.
  • Care should be taken as to not discontinue therapy prematurely.
  • Anti-infective agents should me employed if a bacterial infection is present.
  • Withdrawal of treatment should be carried out by gradually decreasing the frequency of applications when treating chronic conditions.

1% Ophthalmic Solution:
  • Initial dose: Instill 1 to 2 drops into the conjunctival sac of the affected eye(s) up to every hour during the day and every 2 hours during the night as needed
  • Maintenance dose: When a favorable response is observed, reduce dose to 1 drop every 4 hours; subsequent reduction to 1 drop 3 to 4 times a day may be adequate to control symptoms

Comments:
  • Duration of therapy varies depending upon the type of lesion and may extend from a few days to several weeks, based on therapeutic response.
  • Relapses, which are more common in chronic active lesions than in self-limited conditions, usually respond to retreatment.

Uses: For the treatment of steroid responsive mild to moderate noninfectious allergic and inflammatory disorders of the eye (e.g., allergic conjunctivits, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides); and for the treatment of corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies

Usual Adult Dose for Allergic Conjunctivitis

0.12% and 1% Ophthalmic Suspensions: Instill 1 to 2 drops into the conjunctival sac of the affected eye(s) 2 to 4 times a day; during the initial 24 to 48 hours, may increase dosing frequency if necessary

Comments:

  • If signs/symptoms fail to improve after 2 days of treatment, the patient should be re-evaluated.
  • Care should be taken as to not discontinue therapy prematurely.
  • Anti-infective agents should me employed if a bacterial infection is present.
  • Withdrawal of treatment should be carried out by gradually decreasing the frequency of applications when treating chronic conditions.

1% Ophthalmic Solution:
  • Initial dose: Instill 1 to 2 drops into the conjunctival sac of the affected eye(s) up to every hour during the day and every 2 hours during the night as needed
  • Maintenance dose: When a favorable response is observed, reduce dose to 1 drop every 4 hours; subsequent reduction to 1 drop 3 to 4 times a day may be adequate to control symptoms

Comments:
  • Duration of therapy varies depending upon the type of lesion and may extend from a few days to several weeks, based on therapeutic response.
  • Relapses, which are more common in chronic active lesions than in self-limited conditions, usually respond to retreatment.

Uses: For the treatment of steroid responsive mild to moderate noninfectious allergic and inflammatory disorders of the eye (e.g., allergic conjunctivits, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides); and for the treatment of corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies

Usual Adult Dose for Keratitis

0.12% and 1% Ophthalmic Suspensions: Instill 1 to 2 drops into the conjunctival sac of the affected eye(s) 2 to 4 times a day; during the initial 24 to 48 hours, may increase dosing frequency if necessary

Comments:

  • If signs/symptoms fail to improve after 2 days of treatment, the patient should be re-evaluated.
  • Care should be taken as to not discontinue therapy prematurely.
  • Anti-infective agents should me employed if a bacterial infection is present.
  • Withdrawal of treatment should be carried out by gradually decreasing the frequency of applications when treating chronic conditions.

1% Ophthalmic Solution:
  • Initial dose: Instill 1 to 2 drops into the conjunctival sac of the affected eye(s) up to every hour during the day and every 2 hours during the night as needed
  • Maintenance dose: When a favorable response is observed, reduce dose to 1 drop every 4 hours; subsequent reduction to 1 drop 3 to 4 times a day may be adequate to control symptoms

Comments:
  • Duration of therapy varies depending upon the type of lesion and may extend from a few days to several weeks, based on therapeutic response.
  • Relapses, which are more common in chronic active lesions than in self-limited conditions, usually respond to retreatment.

Uses: For the treatment of steroid responsive mild to moderate noninfectious allergic and inflammatory disorders of the eye (e.g., allergic conjunctivits, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides); and for the treatment of corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies

Usual Adult Dose for Cyclitis

0.12% and 1% Ophthalmic Suspensions: Instill 1 to 2 drops into the conjunctival sac of the affected eye(s) 2 to 4 times a day; during the initial 24 to 48 hours, may increase dosing frequency if necessary

Comments:

  • If signs/symptoms fail to improve after 2 days of treatment, the patient should be re-evaluated.
  • Care should be taken as to not discontinue therapy prematurely.
  • Anti-infective agents should me employed if a bacterial infection is present.
  • Withdrawal of treatment should be carried out by gradually decreasing the frequency of applications when treating chronic conditions.

1% Ophthalmic Solution:
  • Initial dose: Instill 1 to 2 drops into the conjunctival sac of the affected eye(s) up to every hour during the day and every 2 hours during the night as needed
  • Maintenance dose: When a favorable response is observed, reduce dose to 1 drop every 4 hours; subsequent reduction to 1 drop 3 to 4 times a day may be adequate to control symptoms

Comments:
  • Duration of therapy varies depending upon the type of lesion and may extend from a few days to several weeks, based on therapeutic response.
  • Relapses, which are more common in chronic active lesions than in self-limited conditions, usually respond to retreatment.

Uses: For the treatment of steroid responsive mild to moderate noninfectious allergic and inflammatory disorders of the eye (e.g., allergic conjunctivits, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides); and for the treatment of corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies

Renal Dose Adjustments

Data not available.

Liver Dose Adjustments

Data not available.

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available.

Other Comments

Administration advice:

  • For topical ophthalmic use only.
  • Suspension: Shake well before use.

Storage requirements:
  • Store in an upright position and keep tightly closed.
  • Protect from freezing.
  • Protect from light.

Patient advice:
  • Avoid allowing the tip of the dropper to touch any surface as this may cause contamination.
  • If irritation persists or develops, discontinue use and consult the prescribing physician.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by